Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COYA 303

Next Previous
Search
Drug Profile

COYA 303

Alternative Names: COY303; COYA 301 + GLP-1 receptor agonist - Coya Therapeutics; COYA-303

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Coya Therapeutics
  • Class Anti-inflammatories; Interleukins
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists; Interleukin 2 replacements; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 21 Apr 2025 Pharmacodynamics data from preclinical study released by Coya Therapeutics
  • 18 Mar 2025 COYA 303 is available for licensing as of 18 Mar 2025. https://coyatherapeutics.com/
  • 18 Mar 2025 Preclinical trials in Inflammation in USA (SC) (Coya Therapeutics pipeline; March 2025)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top